title: The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
abstract: OBJECTIVE
  The objective of this study was to examine the effects of angiotensin II receptor blocker (ARB), used as an antihypertensive medication, on peritoneal membrane transporters in continuous ambulatory peritoneal dialysis (CAPD) patients.
  
  
  METHODS
  Prospective and cross-over experimental study of peritoneal membrane transporters was conducted in 7 CAPD patients with hypertension. All previous antihypertensive drugs had been replaced by candesartan at the dose of 8-16 mg/day to control blood pressure below 140/90 mmHg. Hydralazine, which has no effect on peritoneal membrane transports, was added if the target blood pressure was not achieved. All patients had received candesartan for 12 weeks, then, were retreated with the previous antihypertensive drugs for another 6-week period. The modified peritoneal function tests assessing peritoneal membrane transports were performed at 1) baseline, 2) 6 weeks, 3) 12 weeks following candesartan treatment, and 4) 6 weeks after candesartan withdrawal.
  
  
  RESULTS
  The blood pressure target was achieved in all patients and was not different among the 4 periods. The albumin clearance and 4-hour albumin loss were significantly decreased following candesartan treatment (p < 0.05). Both values returned to the high baseline levels after 6 weeks of candesartan withdrawal. There were no significant changes in net ultrafiltration and various small and large solute transports. No adverse effects, including hyperkalemia or increased erythropoietin dosage, had been observed.
  
  
  CONCLUSIONS
  In hypertensive CAPD patients, candesartan could provide nutritional benefit by attenuating peritoneal loss of albumin and provides an effective antihypertensive action. Furthermore, candesartan does not impair other solute transports and net ultrafiltration.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Prapokklao Chantaburi Hospital.
authors.forename: Virasak
authors.initials: V
authors.lastname: Jearnsujitwimol
authors.forename: Somchai
authors.initials: S
authors.lastname: Eiam-Ong
authors.forename: Talerngsak
authors.initials: T
authors.lastname: Kanjanabuch
authors.forename: Arpar
authors.initials: A
authors.lastname: Wathanavaha
authors.forename: Pongsak
authors.initials: P
authors.lastname: Pansin
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001692:Biological Transport; D001713:Biphenyl Compounds; D001794:Blood Pressure; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008566:Membranes; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods; D010537:Peritoneum; D011446:Prospective Studies; D012709:Serum Albumin / Q000032:analysis; D013777:Tetrazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D012709:Serum Albumin; D013777:Tetrazoles; C081643:candesartan